{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:34:07Z","timestamp":1791466447620,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/nrurol.2010.47","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T12:34:34Z","timestamp":1273235674000},"page":"277-285","source":"Crossref","is-referenced-by-count":636,"title":["The genetic basis of kidney cancer: a metabolic disease"],"prefix":"10.1038","volume":"7","author":[{"given":"W. Marston","family":"Linehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaprasad","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrurol201047_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163\u20132172 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201047_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789\u2013799 (2004).","journal-title":"Nat. Med."},{"key":"BFnrurol201047_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.cell.2009.09.002","volume":"138","author":"CB Thompson","year":"2009","unstructured":"Thompson, C. B. Attacking cancer at its root. Cell 138, 1051\u20131054 (2009).","journal-title":"Cell"},{"key":"BFnrurol201047_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1101\/gad.1756509","volume":"23","author":"RG Jones","year":"2009","unstructured":"Jones, R. G. & Thompson, C. B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23, 537\u2013548 (2009).","journal-title":"Genes Dev."},{"key":"BFnrurol201047_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"BFnrurol201047_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/332268a0","volume":"332","author":"BR Seizinger","year":"1988","unstructured":"Seizinger, B. R.  et al. Von Hippel\u2013Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332, 268\u2013269 (1988).","journal-title":"Nature"},{"key":"BFnrurol201047_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/BF00201543","volume":"86","author":"MI Lerman","year":"1991","unstructured":"Lerman, M. I.  et al. Isolation and regional localization of a large collection (2,000) of single copy DNA fragments on human chromosome 3 for mapping and cloning tumor suppressor genes. Hum. Genet. 86, 567\u2013577 (1991).","journal-title":"Hum. Genet."},{"key":"BFnrurol201047_CR8","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jama.1992.03480090074030","volume":"267","author":"GM Glenn","year":"1992","unstructured":"Glenn, G. M.  et al. Screening for von hippel-lindau disease by DNA-polymorphism analysis. JAMA 267, 1226\u20131231 (1992).","journal-title":"JAMA"},{"key":"BFnrurol201047_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00210739","volume":"90","author":"F Latif","year":"1992","unstructured":"Latif, F.  et al. Molecular and genetic characterization and physical mapping of 11 new markers detecting multiallele restriction fragment length polymorphisms on the short arm of human chromosome 3. Hum. Genet. 90, 17\u201322 (1992).","journal-title":"Hum. Genet."},{"key":"BFnrurol201047_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/jmg.29.12.902","volume":"29","author":"ER Maher","year":"1992","unstructured":"Maher, E. R.  et al. Presymptomatic diagnosis of von Hippel\u2013Lindau disease with flanking DNA markers. J. Med. Genet. 29, 902\u2013905 (1992).","journal-title":"J. Med. Genet."},{"key":"BFnrurol201047_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/hmg\/2.3.279","volume":"2","author":"PA Crossey","year":"1993","unstructured":"Crossey, P. A.  et al. Genetic linkage between von Hippel\u2013Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. Hum. Mol. Genet. 2, 279\u2013282 (1993).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrurol201047_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F.  et al. Identification of the von Hippel\u2013Lindau disease tumor suppressor gene. Science 260, 1317\u20131320 (1993).","journal-title":"Science"},{"key":"BFnrurol201047_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K","volume":"12","author":"C Stolle","year":"1998","unstructured":"Stolle, C.  et al. Improved detection of germline mutations in the von Hippel\u2013Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417\u2013423 (1998).","journal-title":"Hum. Mutat."},{"key":"BFnrurol201047_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R.  et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390 (1994).","journal-title":"Nat. Genet."},{"key":"BFnrurol201047_CR15","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","volume":"14","author":"ML Nickerson","year":"2008","unstructured":"Nickerson, M. L.  et al. Improved identification of von Hippel\u2013Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726\u20134734 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201047_CR16","first-page":"2852","volume":"54","author":"T Shuin","year":"1994","unstructured":"Shuin, T.  et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852\u20132855 (1994).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1126\/science.7660122","volume":"269","author":"DR Duan","year":"1995","unstructured":"Duan, D. R.  et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269, 1402\u20131406 (1995).","journal-title":"Science"},{"key":"BFnrurol201047_CR18","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","volume":"94","author":"A Pause","year":"1997","unstructured":"Pause, A.  et al. The von Hippel\u2013Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156\u20132161 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol201047_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.7660130","volume":"269","author":"A Kibel","year":"1995","unstructured":"Kibel, A., Iliopoulos, O., DeCaprio, J. A. & Kaelin, W. G. Jr. Binding of the von Hippel\u2013Lindau tumor suppressor protein to elongin B and C. Science 269, 1444\u20131446 (1995).","journal-title":"Science"},{"key":"BFnrurol201047_CR20","doi-asserted-by":"publisher","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","volume":"93","author":"O Iliopoulos","year":"1996","unstructured":"Iliopoulos, O., Jiang, C., Levy, A. P., Kaelin, W. G. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel\u2013Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595\u201310599 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol201047_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H.  et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFnrurol201047_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin Jr.","year":"2002","unstructured":"Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673\u2013682 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrurol201047_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel\u2013Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR24","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"BFnrurol201047_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","volume":"1","author":"JK Maranchie","year":"2002","unstructured":"Maranchie, J. K.  et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247\u2013255 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"JD Gordan","year":"2008","unstructured":"Gordan, J. D.  et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435\u2013446 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas, G. V.  et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12, 122\u2013127 (2006).","journal-title":"Nat. Med."},{"key":"BFnrurol201047_CR28","unstructured":"Sun, M., Lughezzani, G., Perrotte, P. & Karakiewicz, P. I. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol. (in press)."},{"key":"BFnrurol201047_CR29","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M.  et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099\u20137109 (2004).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR30","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel, D. B.  et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin. Cancer Res. 9, 327\u2013337 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201047_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe, O.  et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 8, 975\u2013984 (2007).","journal-title":"Lancet Oncol."},{"key":"BFnrurol201047_CR32","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"PA Harris","year":"2008","unstructured":"Harris, P. A.  et al. Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632\u20134640 (2008).","journal-title":"J. Med. Chem."},{"key":"BFnrurol201047_CR33","first-page":"4316","volume":"62","author":"A Rapisarda","year":"2002","unstructured":"Rapisarda, A.  et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316\u20134324 (2002).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-03-3139","volume":"64","author":"A Rapisarda","year":"2004","unstructured":"Rapisarda, A.  et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64, 1475\u20131482 (2004).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR35","unstructured":"National Cancer Institute. A pilot trial of oral topotecan for the treatment of refractory advanced solid neoplasms expressing HIF-1 alpha. NCI-05-C-0186. CCR Clinical Trials at NIH \n                    [online]\n                    \n                  , (2009)."},{"key":"BFnrurol201047_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1087057106289234","volume":"11","author":"GM Woldemichael","year":"2006","unstructured":"Woldemichael, G. M.  et al. Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. J. Biomol. Screen. 11, 678\u2013687 (2006).","journal-title":"J. Biomol. Screen."},{"key":"BFnrurol201047_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas, G. V.  et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12, 122\u2013127 (2006).","journal-title":"Nat. Med."},{"key":"BFnrurol201047_CR38","doi-asserted-by":"publisher","first-page":"34495","DOI":"10.1074\/jbc.C800170200","volume":"283","author":"A Toschi","year":"2008","unstructured":"Toschi, A., Lee, E., Gadir, N., Ohh, M. & Foster, D. A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 283, 34495\u201334499 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol201047_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta, C. M.  et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288\u2013298 (2010).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nsmb1222","volume":"14","author":"M Sanchez","year":"2007","unstructured":"Sanchez, M., Galy, B., Muckenthaler, M. U. & Hentze, M. W. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat. Struct. Mol. Biol. 14, 420\u2013426 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnrurol201047_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nchembio807","volume":"2","author":"TA Rouault","year":"2006","unstructured":"Rouault, T. A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2, 406\u2013414 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"BFnrurol201047_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.tig.2008.05.008","volume":"24","author":"TA Rouault","year":"2008","unstructured":"Rouault, T. A. & Tong, W. H. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 24, 398\u2013407 (2008).","journal-title":"Trends Genet."},{"key":"BFnrurol201047_CR43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/carcin\/bgl210","volume":"28","author":"G Chen","year":"2007","unstructured":"Chen, G., Fillebeen, C., Wang, J. & Pantopoulos, K. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis 28, 785\u2013791 (2007).","journal-title":"Carcinogenesis"},{"key":"BFnrurol201047_CR44","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","volume":"32","author":"M Zimmer","year":"2008","unstructured":"Zimmer, M.  et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838\u2013848 (2008).","journal-title":"Mol. Cell"},{"key":"BFnrurol201047_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","volume":"14","author":"S Turcotte","year":"2008","unstructured":"Turcotte, S.  et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14, 90\u2013102 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR46","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","volume":"12","author":"B Peruzzi","year":"2006","unstructured":"Peruzzi, B. & Bottaro, D. P. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12, 3657\u20133660 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201047_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"LS Schmidt","year":"1997","unstructured":"Schmidt, L. S.  et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68\u201373 (1997).","journal-title":"Nat. Genet."},{"key":"BFnrurol201047_CR48","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/sj.onc.1202547","volume":"18","author":"LS Schmidt","year":"1999","unstructured":"Schmidt, L. S.  et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343\u20132350 (1999).","journal-title":"Oncogene"},{"key":"BFnrurol201047_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","volume":"155","author":"IA Lubensky","year":"1999","unstructured":"Lubensky, I. A.  et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am. J. Pathol. 155, 517\u2013526 (1999).","journal-title":"Am. J. Pathol."},{"issue":"Suppl.","key":"BFnrurol201047_CR50","first-page":"15s","volume":"27","author":"R Srinivasan","year":"2009","unstructured":"Srinivasan, R.  et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET\/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC) [abstract 5103]. J. Clin. Oncol. 27 (Suppl.), 15s (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201047_CR51","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345\u20131356 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol201047_CR52","first-page":"1","volume":"149","author":"J Bjornsson","year":"1996","unstructured":"Bjornsson, J., Short, M. P., Kwiatkowski, D. J. & Henske, E. P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 149, 1\u20138 (1996).","journal-title":"Am. J. Pathol."},{"key":"BFnrurol201047_CR53","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1086\/323744","volume":"69","author":"LS Schmidt","year":"2001","unstructured":"Schmidt, L. S.  et al. Birt\u2013Hogg\u2013Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am. J. Hum. Genet. 69, 876\u2013882 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol201047_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","volume":"2","author":"ML Nickerson","year":"2002","unstructured":"Nickerson, M. L.  et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt\u2013Hogg\u2013Dube syndrome. Cancer Cell 2, 157\u2013164 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR55","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1001\/archderm.1977.01640120042005","volume":"113","author":"AR Birt","year":"1977","unstructured":"Birt, A. R., Hogg, G. R. & Dube, W. J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 113, 1674\u20131677 (1977).","journal-title":"Arch. Dermatol."},{"key":"BFnrurol201047_CR56","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","volume":"26","author":"CP Pavlovich","year":"2002","unstructured":"Pavlovich, C. P.  et al. Renal tumors in the Birt\u2013Hogg\u2013Dub\u00e9 syndrome. Am. J. Surg. Pathol. 26, 1542\u20131552 (2002).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrurol201047_CR57","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1097\/01.ju.0000154629.45832.30","volume":"173","author":"CP Pavlovich","year":"2005","unstructured":"Pavlovich, C. P.  et al. Evaluation and management of renal tumors in the Birt\u2013Hogg\u2013Dube syndrome. J. Urol. 173, 1482\u20131486 (2005).","journal-title":"J. Urol."},{"key":"BFnrurol201047_CR58","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1164\/rccm.200610-1483OC","volume":"175","author":"JR Toro","year":"2007","unstructured":"Toro, J. R.  et al. Lung cysts, spontaneous pneumothrorax and genetic associations in 89 families with Birt\u2013Hogg\u2013Dub\u00e9 syndrome. Am. J. Respir. Crit. Care Med. 175, 1044\u20131053 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrurol201047_CR59","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1086\/430842","volume":"76","author":"LS Schmidt","year":"2005","unstructured":"Schmidt, L. S.  et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt\u2013Hogg\u2013Dub\u00e9 syndrome. Am. J. Hum. Genet. 76, 1023\u20131033 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol201047_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/jmg.2007.054304","volume":"45","author":"JR Toro","year":"2008","unstructured":"Toro, J. R.  et al. BHD mutations, clinical and molecular genetic investigations of Birt\u2013Hogg\u2013Dube syndrome: a new series of 50 families and a review of published reports. J. Med. Genet. 45, 321\u2013331 (2008).","journal-title":"J. Med. Genet."},{"key":"BFnrurol201047_CR61","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/jnci\/dji154","volume":"97","author":"CD Vocke","year":"2005","unstructured":"Vocke, C. D.  et al. High frequency of somatic frameshift BHD gene mutations in Birt\u2013Hogg\u2013Dube-associated renal tumors. J. Natl Cancer Inst. 97, 931\u2013935 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol201047_CR62","doi-asserted-by":"publisher","first-page":"15552","DOI":"10.1073\/pnas.0603781103","volume":"103","author":"M Baba","year":"2006","unstructured":"Baba, M.  et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl Acad. Sci. USA 103, 15552\u201315557 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol201047_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.gene.2008.02.022","volume":"415","author":"H Hasumi","year":"2008","unstructured":"Hasumi, H.  et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415, 60\u201367 (2008).","journal-title":"Gene"},{"key":"BFnrurol201047_CR64","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/onc.2008.261","volume":"27","author":"Y Takagi","year":"2008","unstructured":"Takagi, Y.  et al. Interaction of folliculin (Birt\u2013Hogg\u2013Dube gene product) with a novel Fnip1-like (FnipL\/Fnip2) protein. Oncogene 27, 5339\u20135347 (2008).","journal-title":"Oncogene"},{"key":"BFnrurol201047_CR65","doi-asserted-by":"publisher","first-page":"18722","DOI":"10.1073\/pnas.0908853106","volume":"106","author":"Y Hasumi","year":"2009","unstructured":"Hasumi, Y.  et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc. Natl Acad. Sci. USA 106, 18722\u201318727 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol201047_CR66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jnci\/djm288","volume":"100","author":"M Baba","year":"2008","unstructured":"Baba, M.  et al. Kidney-targeted Birt\u2013Hogg\u2013Dub\u00e9 gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J. Natl Cancer Inst. 100, 140\u2013154 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol201047_CR67","doi-asserted-by":"publisher","first-page":"e3581","DOI":"10.1371\/journal.pone.0003581","volume":"3","author":"J Chen","year":"2008","unstructured":"Chen, J.  et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS ONE 3, e3581 (2008).","journal-title":"PLoS ONE"},{"key":"BFnrurol201047_CR68","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson, I. P.  et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406\u2013410 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrurol201047_CR69","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","volume":"31","author":"MJ Merino","year":"2007","unstructured":"Merino, M. J., Torres-Cabala, C., Pinto, P. A. & Linehan, W. M. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am. J. Surg. Pathol. 31, 1578\u20131585 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrurol201047_CR70","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1001\/archdermatol.2008.517","volume":"144","author":"L Stewart","year":"2008","unstructured":"Stewart, L.  et al. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch. Dermatol. 144, 1584\u20131592 (2008).","journal-title":"Arch. Dermatol."},{"key":"BFnrurol201047_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","volume":"73","author":"JR Toro","year":"2003","unstructured":"Toro, J. R.  et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95\u2013106 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol201047_CR72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jmg.2005.033506","volume":"43","author":"MH Wei","year":"2006","unstructured":"Wei, M. H.  et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J. Med. Genet. 43, 18\u201327 (2006).","journal-title":"J. Med. Genet."},{"key":"BFnrurol201047_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs, J. S.  et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143\u2013153 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrurol201047_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cancergencyto.2009.08.018","volume":"196","author":"Y Yang","year":"2010","unstructured":"Yang, Y.  et al. UOK 262 cell line, fumarate hydratase deficient (FH-\/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 196, 45\u201355 (2010).","journal-title":"Cancer Genet. Cytogenet."},{"key":"BFnrurol201047_CR75","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1128\/MCB.00483-09","volume":"15","author":"S Sudarshan","year":"2009","unstructured":"Sudarshan, S.  et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1{alpha} stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell Biol. 15, 4080\u20134090 (2009).","journal-title":"Mol. Cell Biol."},{"key":"BFnrurol201047_CR76","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/1535-7163.MCT-08-1049","volume":"8","author":"H Xie","year":"2009","unstructured":"Xie, H.  et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 8, 626\u2013635 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrurol201047_CR77","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.287.5454.848","volume":"287","author":"BE Baysal","year":"2000","unstructured":"Baysal, B. E.  et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848\u2013851 (2000).","journal-title":"Science"},{"key":"BFnrurol201047_CR78","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1086\/381054","volume":"74","author":"S Vanharanta","year":"2004","unstructured":"Vanharanta, S.  et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153\u2013159 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrurol201047_CR79","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.292.8.943","volume":"292","author":"HP Neumann","year":"2004","unstructured":"Neumann, H. P.  et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292, 943\u2013951 (2004).","journal-title":"JAMA"},{"key":"BFnrurol201047_CR80","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/djn254","volume":"100","author":"C Ricketts","year":"2008","unstructured":"Ricketts, C.  et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst. 100, 1260\u20131262 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol201047_CR81","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2265.2008.03274.x","volume":"69","author":"U Srirangalingam","year":"2008","unstructured":"Srirangalingam, U.  et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin. Endocrinol. (Oxf.) 69, 587\u2013596 (2008).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrurol201047_CR82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10689-009-9234-z","volume":"8","author":"A Henderson","year":"2009","unstructured":"Henderson, A., Douglas, F., Perros, P., Morgan, C. & Maher, E. R. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam. Cancer 8, 257\u2013260 (2009).","journal-title":"Fam. Cancer"},{"key":"BFnrurol201047_CR83","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer, R. J.  et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584\u20133590 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201047_CR84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science 123, 309\u2013314 (1956).","journal-title":"Science"},{"key":"BFnrurol201047_CR85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/hupa.2002.30210","volume":"33","author":"B Krishnan","year":"2002","unstructured":"Krishnan, B. & Truong, L. D. Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases. Hum. Pathol. 33, 68\u201379 (2002).","journal-title":"Hum. Pathol."},{"key":"BFnrurol201047_CR86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2337\/dc09-1380","volume":"33","author":"GW Landman","year":"2010","unstructured":"Landman, G. W.  et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33, 322\u2013326 (2010).","journal-title":"Diabetes Care"},{"key":"BFnrurol201047_CR87","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JM Evans","year":"2005","unstructured":"Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. & Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304\u20131305 (2005).","journal-title":"BMJ"},{"key":"BFnrurol201047_CR88","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507\u20137511 (2009).","journal-title":"Cancer Res."},{"key":"BFnrurol201047_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/BJ20080557","volume":"412","author":"X Huang","year":"2008","unstructured":"Huang, X.  et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211\u2013221 (2008).","journal-title":"Biochem. J."},{"key":"BFnrurol201047_CR90","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJM200011023431804","volume":"343","author":"WH Chow","year":"2000","unstructured":"Chow, W. H., Gridley, G., Fraumeni, F. J. & Jarvholm, B. Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305\u20131311 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol201047_CR91","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000093918","volume":"77","author":"VA Leitao","year":"2006","unstructured":"Leitao, V. A.  et al. Renal medullary carcinoma. Case report and review of the literature. Urol. Int. 77, 184\u2013186 (2006).","journal-title":"Urol. Int."},{"key":"BFnrurol201047_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","volume":"19","author":"CJ Davis Jr","year":"1995","unstructured":"Davis, C. J. Jr, Mostofi, F. K. & Sesterhenn, I. A. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am. J. Surg. Pathol. 19, 1\u201311 (1995).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrurol201047_CR93","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.med.042808.171650","volume":"10","author":"WM Linehan","year":"2010","unstructured":"Linehan, W. M.  et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 10, 329\u2013343 (2010).","journal-title":"Annu. Rev. Med."},{"key":"BFnrurol201047_CR94","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola, P.  et al. Targeting of HIF-alpha to the von Hippel\u2013Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468\u2013472 (2001).","journal-title":"Science"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.47","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2010.47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:47:22Z","timestamp":1684471642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2010.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFnrurol201047"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2010.47","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}